Table 1 Patient demographics.
From: Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer
Age, years | 73 (67–79) |
|---|---|
Male, n (%) | 184 (80) |
BMI, kg/m2 | 22.2 (19.8–24.2) |
ECOG PS ≥ 1, n (%) | 40 (17) |
CCI ≥ 1, n (%) | 105 (46) |
Neutrophil-to-lymphocyte ratio | 2.2 (1.6–3,2) |
Serum albumin, g/dL | 4.0 (3.3–4.3) |
Psoas muscle index, cm2/m2 | 4.6 (3.6–5.6) |
Average psoas muscle density, HU | 44 (39–47) |
Neoadjuvant chemotherapy, n (%) | 65 (28) |
Cystectomy approach, n (%) | |
Open | 189 (82) |
Laparoscopic | 23 (10) |
Robotic | 18 (8) |
Urinary diversion, n (%) | |
Cutaneous ureterostomy | 91 (40) |
Ileal conduit | 118 (51) |
Neobladder | 21 (9) |
Pathological diagnosis, n (%) | |
UC | 209 (91) |
Non-UC | 21 (9) |
Pathological T stage, n (%) | |
pT0–T2 | 142 (62) |
pT3–T4 | 88 (38) |
Lymph node metastasis | |
pN negative | 189 (82) |
pN positive | 41 (18) |
CIS concurrent | |
Yes | 49 (21) |
No | 181(79) |
